Insights Into Chronic Lymphocytic Leukemia (CLL) 2022
Perspectives of community physicians on the treatment of CLL
Faculty Chair
Deborah Stephens, MD
University of Utah Health, Salt Lake City, UT< USA
Faculty Chair
Marc Hoffmann, MD
University of Kansas Medical Center, Kansas City, KS, USA
Faculty Chair
Deborah Stephens, MD
University of Utah Health, Salt Lake City, UT, USA
Faculty Chair
John Allan, MD
Weill Cornell Medicine, New York, NY, USA
Faculty Chair
Nicole Lamanna, MD
Columbia University Irving Medical Center, New York, NY, USA
Faculty Chair
Seema Bhat, MD
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
Faculty Chair
Nadia Khan, MD
Northwestern Medicine, Chicago, IL, USA
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual series
- Puerto Rico
More Information
- Philadelphia, PA
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of CLL
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, and BR
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region